Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma-Reference-Cited by-同舟云学术

Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma

Published:2019-01 Issue:5 Volume:8 Page:e1050
ISSN:2050-0068
Container-title:Clinical & Translational Immunology
language:en
Short-container-title:Clin Transl Immunol

Author:

Brown Michael P¹²³,Ebert Lisa M¹,Gargett Tessa¹

Affiliation:

1. Translational Oncology Laboratory Centre for Cancer Biology University of South Australia and SA Pathology Adelaide SA Australia

2. Cancer Clinical Trials Unit Royal Adelaide Hospital Adelaide SA Australia

3. School of Medicine University of Adelaide Adelaide SA Australia

Funder

Cancer Council South Australia

Hospital Research Foundation

Publisher

Wiley

Subject

General Nursing,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cti2.1050

Reference111 articles.

1. Current state of immunotherapy for glioblastoma

2. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

3. Therapeutic T cell engineering

4. Australian Institute of Health and Welfare.Brain and other central nervous system cancers.2017; Cat. no. CAN 106.Canberra:AIHW.

5. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment;Hanif F;Asian Pac J Cancer Prev,2017

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bayesian network analysis of risk classification strategies in the regulation of cellular products;Artificial Intelligence in Medicine;2024-09

2. Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma;Clinical & Translational Immunology;2024-01

3. Advances in Glioblastoma Therapy: An Update on Current Approaches;Brain Sciences;2023-10-31

4. Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma;Frontiers in Immunology;2023-10-20

5. An updated overview of the application of CAR‐T cell therapy in neurological diseases;Biotechnology Progress;2023-05-17